Qure.ai Partners With Microsoft to Expand Access to Lung Cancer Detection and Management AI Suite in the U.S.

The move is expected to widen access to early detection tools and reduce clinical workflow burdens in one of the country’s highest-mortality disease areas.

Qure.ai has announced a collaboration with Microsoft to integrate its AI-powered lung cancer detection and management solutions with the Microsoft Precision Imaging Network, enabling streamlined deployment across hospitals and health systems in the United States.

The move is expected to widen access to early detection tools and reduce clinical workflow burdens in one of the country’s highest-mortality disease areas.

Lung cancer remains the leading cause of cancer deaths in the U.S., surpassing colon, breast, and prostate cancers combined. Qure.ai’s suite—developed using Large Language Models (LLMs) and Agentic AI—supports workflow coordination between radiologists, pulmonologists, interventionalists, and thoracic surgery teams. The tools aim to speed the transition from initial detection to diagnosis and treatment within multidisciplinary care settings.

Jim Mercadante, Chief Commercial Officer at Qure.ai, said the collaboration “brings new levels of choice and simplicity for hospitals and health systems across the USA,” enabling improved access to early detection, triage, and patient tracking. He added that the partnership strengthens Qure.ai’s expanding network of alliances across academia, government, pharma, life sciences, and technology. Mercadante highlighted the company’s recent five-million-scan milestone achieved through its long-term partnership with AstraZeneca and the EDISON Alliance, using routine chest X-rays for early lung cancer risk identification across 20 countries.

Peter Durlach, Corporate VP and Chief Strategy Officer, Microsoft Health and Life Sciences, said the integration will help health systems “unlock new levels of efficiency,” supporting faster detection, more coordinated care, and earlier clinical interventions through secure and scalable cloud-based AI.

Qure.ai currently operates in more than 105 countries and over 4,800 sites globally. The company, recognized as a TIME100 Most Influential Company in 2025, holds 19 FDA clearances covering lung cancer and neurocritical findings. These capabilities are designed to support clinicians across detection, triage, and management workflows.

The lung cancer suite can be deployed as standalone tools or collectively for an integrated workflow. Solutions include qXR-LN for incidental nodule detection on chest X-rays, qCT-LN Quant for CT-based measurement and quantification, and qTrack for coordinated patient management. The company’s neurocritical care tool, qER, provides triage support for emergency findings to facilitate timely interventions.

Stay tuned for more such updates on Digital Health News